As the therapeutic potential of psychedelics is becoming more established, a wider range of compounds are beginning to be investigated for their antidepressant properties. 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is one such example; its unusual properties may make it a more cost-effective and practical choice for health care providers. However, the same distinctive features may mean that its potential for success as a mainstream treatment option for depression is limited. There is very little existing literature around 5-MeO-DMT, and it is scarcely used even within the psychedelics community. This may mean that it is even more difficult to recruit a diverse range of subjects, which is already an issue for clinical trials involving other psychedelics. The aim of this article is to discuss the hypothetical pros and cons of 5-MeO-DMT as an antidepressant and to make recommendations for measures to be taken in any future clinical trials investigating 5-MeO-DMT.
Get full access to this article
View all access options for this article.
References
1.
SiegelAN, MeshkatS, BenitahK, et al.Registered clinical studies investigating psychedelic drugs for psychiatric disorders. J Psychiatr Res, 2021; 139:71–81; doi: 10.1016/j.jpsychires.2021.05.019
2.
ReckwegJ, MasonN, van LeeuwenL, et al.A phase 1, dose-ranging study to assess safety and psychoactive effects of a vaporized 5-Methoxy-N, N-Dimethyltryptamine formulation (GH001) in healthy volunteers. Front Pharmacol, 2021; 12:760671; doi: 10.3389/fphar.2021.760671
3.
BarsugliaJP, PolancoM, PalmerR, et al.A case report SPECT study and theoretical rationale for the sequential administration of ibogaine and 5-MeO-DMT in the treatment of alcohol use disorder. Prog Brain Res, 2018; 242:121–158; doi: 10.1016/bs.pbr.2018.08.002
4.
DavisAK, SoS, LancelottaR, et al.5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. Am J Drug Alcohol Abuse, 2019; 45(2):161–169; doi: 10.1080/00952990.2018.1545024
5.
ReckwegJT, van LeeuwenCJ, HenquetC, et al.A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression. Front Psychiatry, 2023; 14:1133414; doi: 10.3389/fpsyt.2023.1133414
6.
KwaśnyA, WilkowskaA, CubałaWJ. Short-term safety and tolerability profile of 5-methoxy-N,N-dimethyltryptamine in human subjects: A systematic review of clinical trials. Front Psychiatry, 2024; 15:1477996; doi: 10.3389/fpsyt.2024.1477996
7.
SherwoodAM, ClaveauR, LancelottaR, et al.Synthesis and characterization of 5-MeO-DMT succinate for clinical use. ACS Omega, 2020; 5(49):32067–32075; doi: 10.1021/acsomega.0c05099
8.
UthaugMV, LancelottaR, Ortiz BernalAM, et al.A comparison of reactivation experiences following vaporization and Intramuscular Injection (IM) of synthetic 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting. J Psychedelic Studies, 2020; 4(2):104–113; doi: 10.1556/2054.2020.00123
9.
BarsugliaJ, DavisAK, PalmerR, et al.Intensity of mystical experiences occasioned by 5-MeO-DMT and comparison with a prior psilocybin study. Front Psychol, 2018; 9:2459; doi: 10.3389/fpsyg.2018.02459
10.
RosemanL, NuttDJ, Carhart-HarrisRL. Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin for treatment-resistant depression. Front Pharmacol, 2017; 8:974; doi: 10.3389/fphar.2017.00974
11.
ShenHW, JiangXL, WinterJC, et al.Psychedelic 5-methoxy-N,N-dimethyltryptamine: Metabolism, pharmacokinetics, drug interactions, and pharmacological actions. Curr Drug Metab, 2010; 11(8):659–666; doi: 10.2174/138920010794233495
12.
HalberstadtAL, NicholsDE, GeyerMA. Behavioral effects of alpha,alpha,beta,beta-tetradeutero-5-MeO-DMT in rats: Comparison with 5-MeO-DMT administered in combination with a monoamine oxidase inhibitor. Psychopharmacology (Berl), 2012; 221(4):709–718; doi: 10.1007/s00213-011-2616-6
13.
ErmakovaAO, DunbarF, RuckerJ, et al.A narrative synthesis of research with 5-MeO-DMT. J Psychopharmacol, 2022; 36(3):273–294; doi: 10.1177/02698811211050543
14.
HoshinoT, ShimodairaK. Über die synthese des Bufotenin-Methyl-Äthers (5-Methoxy-N-Dimethyl-Tryptamin) Und Bufotenins (Synthesen In Der Indol-Gruppe. Xv). Bulletin of the Chemical Society of Japan, 1936; 11(3):221–224.
15.
MostA. Bufo Alvarius: The Psychedelic Toad of the Sonoran Desert. Venom Press: Denton, TX; 1984.
ReckwegJT, UthaugMV, SzaboA, et al.The clinical pharmacology and potential therapeutic applications of 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT). J Neurochem, 2022; 162(1):128–146; doi: 10.1111/jnc.15587
18.
HayesC, WahbaM, WatsonS. Will psilocybin lose its magic in the clinical setting? Ther Adv Psychopharmacol, 2022; 12:20451253221090822; doi: 10.1177/20451253221090822
19.
DavisAK, BarsugliaJ, LancelottaR, et al.The epidemiology of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use, subjective effects, and reasons for consumption. J Psychopharmacol, 2018; 32(7):779–792; doi: 10.1177/0269881118769063
20.
DakwarE. Amphibious anti-depressants and other wonders. Am J Drug Alcohol Abuse, 2019; 45(2):115–116; doi: 10.1080/00952990.2019.1580288
21.
CarbonaroTM, JohnsonMW, HurwitzE, et al.Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: Similarities and differences in subjective experiences. Psychopharmacology (Berl), 2018; 235(2):521–534; doi: 10.1007/s00213-017-4769-4
22.
SmithALW, HarmerCJ, CowenPJ, et al.The serotonin 1A (5-HT1A) receptor as a pharmacological target in depression. CNS Drugs, 2023; 37(7):571–585; doi: 10.1007/s40263-023-01014-7
23.
KishiT, MeltzerHY, MatsudaY, et al.Azapirone 5-HT1A receptor partial agonist treatment for major depressive disorder: Systematic review and meta-analysis. Psychol Med, 2014; 44(11):2255–2269; doi: 10.1017/S0033291713002857
24.
LoaneC, PolitisM. Buspirone: What is it all about? Brain Res, 2012; 1461:111–118; doi: 10.1016/j.brainres.2012.04.032
25.
DepoortereR, AuclairAL, Newman-TancrediA. NLX-101, a highly selective 5-HT(1A) receptor biased agonist, mediates antidepressant-like activity in rats via prefrontal cortex 5-HT(1A) receptors. Behav Brain Res, 2021; 401:113082; doi: 10.1016/j.bbr.2020.113082
26.
WarrenAL, LankriD, CunninghamMJ, et al.Structural pharmacology and therapeutic potential of 5-methoxytryptamines. Nature, 2024; 630(8015):237–246; doi: 10.1038/s41586-024-07403-2
27.
RuckerJJ, RobertsC, SeynaeveM, et al.Phase 1, placebo-controlled, single ascending dose trial to evaluate the safety, pharmacokinetics and effect on altered states of consciousness of intranasal BPL-003 (5-methoxy-N,N-dimethyltryptamine benzoate) in healthy participants. J Psychopharmacol, 2024; 38(8):712–723; doi: 10.1177/02698811241246857
GoodwinGM, AaronsonST, AlvarezO, et al.Single-Dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med, 2022; 387(18):1637–1648; doi: 10.1056/NEJMoa2206443
32.
PalamarJJ, AcostaP. A qualitative descriptive analysis of effects of psychedelic phenethylamines and tryptamines. Hum Psychopharmacol, 2020; 35(1):e2719; doi: 10.1002/hup.2719
33.
PalamarJJ, LeA. Trends in DMT and other tryptamine use among young adults in the United States. Am J Addict, 2018; 27(7):578–585; doi: 10.1111/ajad.12803
34.
SextonJD, NicholsCD, HendricksPS. Population survey data informing the therapeutic potential of classic and novel phenethylamine, tryptamine, and lysergamide psychedelics. Front Psychiatry, 2019; 10:896; doi: 10.3389/fpsyt.2019.00896
35.
GriffithsRR, JohnsonMW, RichardsWA, et al.Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. J Psychopharmacol, 2018; 32(1):49–69; doi: 10.1177/0269881117731279
36.
BarrettFS, JohnsonMW, GriffithsRR. Validation of the revised mystical experience questionnaire in experimental sessions with psilocybin. J Psychopharmacol, 2015; 29(11):1182–1190; doi: 10.1177/0269881115609019
37.
PetersenR. A Theological Reckoning with ‘Bad Trips’. Harvard Divinity Bulletin; 2020.
38.
Acosta-UrquidiJ. QEEG. Studies of the acute effects of the visionary tryptamine DMT. Cosmos and History-the J Natur Social Philosophy, 2015; 11:115–129.
39.
MilliereR, Carhart-HarrisRL, RosemanL, et al.Psychedelics, meditation, and self-consciousness. Front Psychol, 2018; 9:1475; doi: 10.3389/fpsyg.2018.01475
40.
BathjeGJ, MajeskiE, KudoworM. Psychedelic integration: An analysis of the concept and its practice. Front Psychol, 2022; 13:824077; doi: 10.3389/fpsyg.2022.824077
41.
WattsR, LuomaJB. The use of the psychological flexibility model to support psychedelic assisted therapy. J Contextual Behav Sci, 2020; 15:92–102; doi: 10.1016/j.jcbs.2019.12.004
42.
Lopez-ArnauR, CamarasaJ, CarboML, et al.3,4-Methylenedioxy methamphetamine, synthetic cathinones and psychedelics: From recreational to novel psychotherapeutic drugs. Front Psychiatry, 2022; 13:990405; doi: 10.3389/fpsyt.2022.990405
43.
PollanM. How to Change Your Mind. Penguin Random House; 2018.
HayesC. Psychedelics in the Clinical Setting: The Potential for Harm and the Promise of Healing. Bill of Health. Petrie-Flom Center, Harvard University; 2024.
46.
ShenHW, WuC, JiangXL, et al.Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics. Biochem Pharmacol, 2010; 80(1):122–128; doi: 10.1016/j.bcp.2010.02.020
47.
NeumannJ, SchulzN, FehseC, et al.Cardiovascular effects of bufotenin on human 5-HT(4) serotonin receptors in cardiac preparations of transgenic mice and in human atrial preparations. Naunyn Schmiedebergs Arch Pharmacol, 2023; 396(7):1471–1485; doi: 10.1007/s00210-023-02414-8
48.
UthaugMV, LancelottaR, SzaboA, et al.Prospective examination of synthetic 5-methoxy-N,N-dimethyltryptamine inhalation: Effects on salivary IL-6, cortisol levels, affect, and non-judgment. Psychopharmacology (Berl), 2020; 237(3):773–785; doi: 10.1007/s00213-019-05414-w
49.
Ortiz BernalA, RaisonC, LancelottaR, et al.Reactivations after 5-methoxy-N,N-dimethyltryptamine use in naturalistic settings: An initial exploratory analysis of the phenomenon’s predictors and its emotional valence. Front Psychiatry, 2022; 13:1049643; doi: 10.3389/fpsyt.2022.1049643
Health Do. Reference Guide to Consent for Examination or Treatment. Second edition. Health Do: London; 2009.
54.
JacobsE. Transformative experience and informed consent to psychedelic-assisted psychotherapy. Front Psychol, 2023; 14:1108333; doi: 10.3389/fpsyg.2023.1108333
55.
VilligerD. Giving consent to the Ineffable. Neuroethics, 2024; 17(1):11; doi: 10.1007/s12152-024-09545-6
56.
MatzopoulosR, MorlockR, MorlockA, et al.Corrigendum: Psychedelic mushrooms in the USA: Knowledge, patterns of use, and association with health outcomes. Front Psychiatry, 2022; 13:877390; doi: 10.3389/fpsyt.2022.877390
57.
LancelottaR, DavisAK. Use of benefit enhancement strategies among 5-Methoxy-N,N-dimethyltryptamine (5-MeO-DMT) users: Associations with mystical, challenging, and enduring effects. J Psychoactive Drugs, 2020; 52(3):273–281.
58.
TittarelliR, MannocchiG, PantanoF, et al.Recreational use, analysis and toxicity of tryptamines. Curr Neuropharmacol, 2015; 13(1):26–46; doi: 10.2174/1570159X13666141210222409
UthaugMV, LancelottaR, van OorsouwK, et al.A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness-related capacities, and a decrement of psychopathological symptoms. Psychopharmacology (Berl), 2019; 236(9):2653–2666; doi: 10.1007/s00213-019-05236-w
61.
SellersEM, RomachMK, LeidermanDB. Studies with psychedelic drugs in human volunteers. Neuropharmacology, 2018; 142:116–134; doi: 10.1016/j.neuropharm.2017.11.029
